(Q73599594)

English

Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab

scientific article published on 01 April 2000

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

based on heuristic

inferred from title

author name string

M A Mascelli

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

N S Kleiman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

S J Marciniak

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

L Damaraju

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

H F Weisman

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

R E Jordan

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

language of work or name

0 references

publication date

1 April 2000

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

139

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

696-703

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Reactivation of unstable angina after the discontinuation of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

The Platelet Aggregating Effect of Eight Commercial Heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Effect of Heparin and Heparin Fractions on Platelet Aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

On the mechanism of platelet aggregation induced by heparin, protamine and polybrene

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Inhibition of Thrombin Induced Aggregation of Human Platelets by Heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Heparin-binding platelet proteins demonstrated by crossed affinity immunoelectrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Characterization of platelet binding of heparins and other glycosaminoglycans

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Domains specifying thrombin–receptor interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complicatio

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Effects of the Numbers and Sizes of Platelet Aggregates on the Optical Density of Plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990050-4

7 January 2021

Identifiers

10.1016/S0002-8703(00)90050-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740154%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73599594&oldid=2233914568"